ClinicalTrials.gg
Active, not recruitingNCT06200207ATHENAUpdated Oct 1, 2026

A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation

A Phase 3 interventional study of Ziltivekimab and Placebo in Heart Failure and Systemic Inflammation, sponsored by Novo Nordisk A/S. Active, not recruiting at 217 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Updated Oct 1, 2026Enrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
673
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies in Heart Failure by Novo Nordisk A/S — 5 open to participants now, 6 under way, 2 of them phase 3. Heart Failure · Novo Nordisk A/S.

Planned enrollment
3rd of 11
673 · median 200
Started
2024
with 2 others
Phase 3
3 of 14
1 open now
Registered
6th of 14
by date

Among the 14 studies in Heart Failure by Novo Nordisk A/S, this one is the 3rd largest by planned enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2024, is one of 3 in phase 3, and was the 6th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.

Browse Heart Failure studies →

Open to participants now

5 of the 14 studies in Heart Failure by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Heart Failure by Novo Nordisk A/S, or all of them as a file.
02

Study summary

The study is being done to see if ziltivekimab can be used to treat participants living with heart failure and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (inactive substance that looks like the study medicine but does not contain any medicine). The treatment participants get is decided by chance. Participant's chance of getting ziltivekimab or placebo is the same. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe. The study is expected to last for up to 1 year and 4 months.

03

Conditions studied

  • Heart Failure
  • Systemic Inflammation

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Serum high-sensitivity C-reactive protein (hs-CRP) greater than or equal to 2 milligrams per liter (mg/L) at screening (visit 1)
  • Disease specific - cardiovascular:
  • N-terminal-pro-brain natriuretic peptide (NT-proBNP) greater than or equal to 225 picograms per milliliter (pg/mL) (375 pg/mL for participants with atrial fibrillation/flutter) at screening
  • Diagnosis of heart failure ( (NYHA) Class II-III)
  • (LVEF) greater than 40 percent documented by echocardiography within 12 months prior to or at screening (visit 1). The LVEF must be documented in medical records and the most recent measurement must be used to determine eligibility with no interim event signalling potential deterioration in ejection fraction (example myocardial infarction (MI) or heart failure (HF) hospitalisation)
  • Structural heart disease and/or functional heart disease documented by echocardiography within 12 months prior to or at screening (visit 1) showing at least one of the following:

    1. Left atrial (LA) volume index greater than 34 milliliter per square meter (mL/m\^2)
    2. LA diameter greater than or equal to 3.8 centimeters (cm)
    3. LA length greater than or equal to 5.0 cm
    4. LA area greater than or equal to 20 square centimeters (cm\^2)
    5. LA volume greater than or equal to 55 milliliters (mL)
    6. Intraventricular septal thickness greater than or equal to 1.1 cm
    7. Posterior wall thickness greater than or equal to 1.1 cm
    8. LV mass index greater than or equal to 115 grams per square meter (g/m\^2) in men or greater than or equal to 95 g/m\^2 in women

    h) E/e' (mean septal and lateral) greater than or equal to 10 i) e' (mean septal and lateral) less than 9 centimeters per second (cm/s)

  • No heart failure hospitalisations or urgent heart failure visits between screening and randomisation
  • Able to perform the 6-minute walk test (6MWT) at screening with a minimum distance of 100 metres
  • Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score lesser than 80 at screening

Exclusion criteria

Exclusion Criteria:

  • Medical conditions - cardiovascular:
  • Myocardial infarction, stroke, unstable angina pectoris, , or heart failure hospitalisation within 30 days prior to screening (visit 1)
  • Systolic blood pressure greater than or equal to 180 millimeters of mercury (mmHg) at screening (visit 1). If the systolic blood pressure is 160-179 mmHg, the patient should be receiving greater than or equal to 3 antihypertensive drugs
  • Heart rate above 110 or below 40 beats per minute as evaluated on the (ECG) performed at screening (visit 1)
  • Planned coronary, carotid or peripheral artery revascularisation known during the screening period (visit 1)
  • Planned cardiac device or atrial flutter/atrial fibrillation ablation procedure known during the screening period (visit 1)
  • Major cardiac surgical, non-cardiac surgical, or major endoscopic procedure (thoracoscopic or laparoscopic) within the past 60 days prior to randomisation (visit 2) or any major surgical procedure planned at the time of randomisation (visit 2)
  • Heart failure due to infiltrative cardiomyopathy (e.g., sarcoid, amyloid), arrhythmogenic right ventricular cardiomyopathy, Takutsubo cardiomyopathy, genetic hypertrophic cardiomyopathy or obstructive cardiomyopathy, active myocarditis, constrictive pericarditis, cardiac tamponade, uncorrected more than moderate primary valve disease
  • Primary pulmonary hypertension, chronic pulmonary embolism, severe pulmonary disease including (COPD)
  • Any other condition judged by the investigator that could account for heart failure symptoms and signs (e.g., anaemia, hypothyroidism)
  • Medical conditions - infections/:
  • Clinical evidence of, or suspicion of, active infection at the discretion of the investigator
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
673 participants (estimated)

Study arms

  • Active comparator
    Ziltivekimab

    Participants will receive ziltivekimab administered subcutaneously (s.c.) once-monthly and added to standard of care for 12 months.

    Drug: Ziltivekimab

  • Placebo comparator
    Placebo

    Participants will receive placebo matched to ziltivekimab administered s.c. once-monthly and added to standard of care for 12 months.

    Drug: Placebo

Interventions

  • Zilitivekimab will be administered subcutaneously once-monthly.

  • DrugPlacebo

    Placebo matched to ziltivekimab will be administered subcutaneously once-monthly.

06

What researchers measure

Primary outcomes

  1. Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score (KCCQ-CSS)

    Measured as score (score on scale; range; 0-100). The KCCQ is a disease-specific health status instrument composed of 23 items that quantify the domains of physical limitation, symptoms, self-efficacy, social limitation, and health-related quality of life limitation from heart failure. The overall summary score and all domains have been independently demonstrated to be valid, reliable, and responsive to clinical change. CSS scores range from 0 to 100 and lower scores represent more severe symptoms and/or limitations and scores of 100 indicate no symptoms, no limitations, and excellent quality of life.

    Time frame: From randomisation (month 0) to end-of-treatment (month 12)

Secondary outcomes

  1. Participant achieving threshold for clinically meaningful within-participant change in KCCQ CSS (yes/no)

    Measured as count of participants. The KCCQ is a disease-specific health status instrument composed of 23 items that quantify the domains of physical limitation, symptoms, self-efficacy, social limitation, and health-related quality of life limitation from heart failure. The overall summary score and all domains have been independently demonstrated to be valid, reliable, and responsive to clinical change. CSS scores range from 0 to 100 and lower scores represent more severe symptoms and/or limitations and scores of 100 indicate no symptoms, no limitations, and excellent quality of life.

    Time frame: From randomisation (month 0) to end-of-treatment (month 12)

  2. Participant achieving threshold for clinically meaningful within-participant change in 6-minute walk distance (6MWD) (yes/no)

    Measured as count of participants.

    Time frame: From randomisation (month 0) to end-of-treatment (month 12)

  3. Participants improving 5 points or more in KCCQ-CSS (yes/no)

    Measured as count of participants. The KCCQ is a disease-specific health status instrument composed of 23 items that quantify the domains of physical limitation, symptoms, self-efficacy, social limitation, and health-related quality of life limitation from heart failure. The overall summary score and all domains have been independently demonstrated to be valid, reliable, and responsive to clinical change. CSS scores range from 0 to 100 and lower scores represent more severe symptoms and/or limitations and scores of 100 indicate no symptoms, no limitations, and excellent quality of life.

    Time frame: From randomisation (month 0) to end-of-treatment (month 12)

  4. Participants improving 10 points or more in KCCQ-CSS (yes/no)

    Measured as count of participants. The KCCQ is a disease-specific health status instrument composed of 23 items that quantify the domains of physical limitation, symptoms, self-efficacy, social limitation, and health-related quality of life limitation from heart failure. The overall summary score and all domains have been independently demonstrated to be valid, reliable, and responsive to clinical change. CSS scores range from 0 to 100 and lower scores represent more severe symptoms and/or limitations and scores of 100 indicate no symptoms, no limitations, and excellent quality of life.

    Time frame: From randomisation (month 0) to end-of-treatment (month 12)

  5. Change in subscales of KCCQ (total symptom score, physical limitations score, social limitations score, and health-related quality of life)

    Measured as score (score on scale; range 0-100). The KCCQ is a disease-specific health status instrument composed of 23 items that quantify the domains of physical limitation, symptoms, self-efficacy, social limitation, and health-related quality of life limitation from heart failure. The overall summary score and all domains have been independently demonstrated to be valid, reliable, and responsive to clinical change. CSS scores range from 0 to 100 and lower scores represent more severe symptoms and/or limitations and scores of 100 indicate no symptoms, no limitations, and excellent quality of life.

    Time frame: From randomisation (month 0) to end-of-treatment (month 12)

  6. Change in six-minute walk distance (6MWD)

    Measured in meters.

    Time frame: From randomisation (month 0) to end-of-treatment (month 12)

  7. Change in high-sensitivity C-reactive protein (hs-CRP)

    Measured as ratio to baseline.

    Time frame: From randomisation (month 0) to end-of-treatment (month 12)

  8. Participants experiencing improvement in New York heart association (NYHA) Class (yes/no)

    Measured as count of participants. The New York Heart Association (NYHA) classification provides a simple way of classifying the extent of heart failure (HF). It classifies patients in one of four categories based on their limitations during physical activity - Class I: Participant with cardiac disease but without resulting limitations of physical activity, Class II: Participants with cardiac disease resulting in slight limitation of physical activity, Class III: Participants with cardiac disease resulting in marked limitation of physical activity, Class IV: Participants with cardiac disease resulting in inability to carry on any physical activity without discomfort.

    Time frame: From randomisation (month 0) to end-of-treatment (month 12)

  9. Change in N-terminal-pro-brain natriuretic peptide (NT-proBNP)

    Measured as ratio to baseline.

    Time frame: From randomisation (month 0) to end-of-treatment (month 12)

  10. Change in eGFR (CKD-EPI)

    eGFR (CKD-EPI) is estimated glomerular filtration rate chronic kidney disease - epidemiology collaboration. Measured in milliliter per minute per 1.73 square meter (ml/min/1.73\^2).

    Time frame: From randomisation (month 0) to end-of-treatment (month 12)

07

Study locations

217 sites

Showing the first 100 of 217 sites across 16 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Oct 2026, 30 months after the start.

Of 63 industry-sponsored phase 3 interventional studies under Heart Failure, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 44. This study's planned 30 months is below that.

Counting every sponsor, half of 151 studies reached it within 39 months; a quarter within 25 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 28, 2023
First posted
Jan 10, 2024
StartActual
Apr 1, 2024
Primary completionEst.
Oct 1, 2026
CompletionEst.
Jan 8, 2027
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
680→673
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Enrollment 680→673
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06200207
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jan 10, 2024
Start date
Apr 1, 2024
Primary completion
Oct 1, 2026 (estimated)
Completion
Jan 8, 2027 (estimated)
Last update
Oct 1, 2026

Study contacts

Clinical Transparency dept. 2834
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ziltivekimab

Start the discussion